Carotuximab, also known as TRC105 or DE-122, represents a novel antibody-drug conjugate therapeutic currently being studied for combating various cancerous diseases. This distinct molecule targets a specific antigen, found on cancer cells, releasing a potent cytotoxic substance directly within the diseased area. Early clinical studies have shown pr

The arrival of amivantamab represents a exciting advance for people battling cancers featuring c-MET dysregulation. This unique molecule, a precise agent of both MET kinase plus human epidermal growth factor receptor 2 (HER2), demonstrated encouraging results in clinical trials, particularly in individuals whose tumors harbor exhibitable c-MET exon